Effect of silymarin on the liver and pain of rheumatoid arthritis patients

Effect of Silybum marianum on methotrexate-induced hepatotoxicity and its analgesic effect in the patients with rheumatoid arthritis history

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180519039711N4

Enrollment

Registered

2020-02-04

Start date

2020-02-20

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis. Rheumatoid arthritis with rheumatoid factor

Interventions

Intervention 1: Intervention group: Take daily with oral 280-mg Silymarin ?For 2 months. Intervention 2: Control group: Control group take under the administration of placebo.

Eligibility

Sex/Gender

All

Age

16 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age between 16 and 85 No history of liver disease taking methotrexate Diagnosis of rheumatoid arthritis with criteria American Collage of Rhematology

Exclusion criteria

Exclusion criteria: Unwilling to continue studying Discharge or death of the patient Sensitivity to methotrexate

Design outcomes

Primary

Measure	Time frame
???. Timepoint: Before and 60 Day after intervention. Method of measurement: Visual Analogue Scale.;Hepatotoxicity. Timepoint: Before and 60 Day after intervention. Method of measurement: check list.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactmasoume garshasbi

Arak University of Medical Sciences

garshasbimasoume@gmail.com+98 86 3417 3503

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026